drugset / Trial / NCT05253131
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Phase 2
Not yet recruiting
41 enrolled
University of Alabama at Birmingham
Children's Hospital of Philadelphia · collabCongressionally Directed Medical Research Programs · collab
NaSequentialOpen-labelTreatment
Summary
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.
Timeline
- Start
- 2026-11-15
- Primary completion
- 2031-11-15
- Completion
- 2032-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Selumetinib | Small molecule | — | — |
| Subject | ZEN-3694 | Small molecule | — | — |